LEO PHARMA A/S
Registration details
Company overview
LEO Pharma A/S is a private limited company (Aktieselskab) registered in Denmark under CVR (Central Business Register) number 56759514. The company was incorporated on 10 February 1962 and is currently recorded with active status in the Danish Business Authority’s CVR register. Its registered address is Industriparken 55, 2750 Ballerup, Denmark.
LEO Pharma A/S is a pharmaceutical company focused on medical dermatology. It researches, develops, manufactures and markets prescription and over-the-counter treatments for skin conditions, including psoriasis, actinic keratosis and other inflammatory and chronic dermatological diseases, alongside a legacy portfolio addressing other specialty conditions. LEO Pharma operates through a global network of affiliated entities and distributes its products in more than 100 countries, with manufacturing and commercial operations spanning Europe, North America and Asia-Pacific.
LEO Pharma A/S is not listed on any stock exchange and has no publicly traded shares or ticker symbol.
Based on published 2024 annual results covering the wider LEO Pharma organisation, consolidated group revenue reached DKK 12,453 million for the 2024 financial year, a reported 10% increase at constant exchange rates, with adjusted EBITDA of DKK 895 million and a net loss of DKK 1,776 million, narrower than the DKK 3,607 million loss reported for 2023. The wider organisation reported approximately 4,000 employees operating in over 100 countries as of the 2024 financial year. These figures reflect consolidated results reported for the LEO Pharma group and should not be read as standalone financial statements for the Danish legal entity LEO Pharma A/S.
No dissolution date is recorded for the company, and no material recent regulatory filings specific to the legal entity were identified beyond the group-level annual results referenced above.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Officers
82
Directors and officers of LEO Pharma A/S
The Danish CVR register holds 82 officer-related records for LEO Pharma A/S; the data extract available for this profile includes five records, all currently active with no resignation date recorded. Disclosed roles among these five include Chairman of the Board ("Formand") and Board Member ("Bestyrelsesmedlem"). Two further individuals in the same extract are recorded under the separate "Reelle ejere" (beneficial owner) designation rather than as directors or officers and are addressed in the shareholders/UBO section of this profile instead.
Jesper Brandgaard is recorded as Chairman of the Board of Directors ("Formand") in the CVR extract. This is corroborated by LEO Pharma’s and the LEO Foundation’s own announcements, which state that Jesper Brandgaard β previously Group CFO of Novo Nordisk for more than 17 years β became Chairman of LEO Pharma’s Board of Directors effective 1 August 2021.
Aage Spang-Hanssen and Carl-Aage Lund are recorded as Board Members ("Bestyrelsesmedlem") in the CVR register, both with active status. No independent secondary source was located to corroborate these two specific appointments beyond the CVR register itself.
Nationality is not disclosed for any individual in the reviewed CVR extract. A correspondence address is recorded in Denmark for two of the individuals; this is treated strictly as a service address and not as evidence of nationality or residence.
LEO Pharma’s own corporate website separately identifies Christophe Bourdon as Chief Executive Officer, effective 1 April 2022, previously CEO of Orphazyme A/S. This appointment could not be cross-matched to a specific record within the five-record CVR extract available (out of 82 total) and is included here for completeness based on the company’s own governance disclosures.
Recent officer changes
- Jesper Brandgaard appointed Chairman of the Board of Directors, effective 1 August 2021 (source: LEO Foundation).
- Christophe Bourdon appointed Chief Executive Officer, effective 1 April 2022 (source: LEO Pharma corporate website).
Data availability
Officer information for LEO Pharma A/S is partial: the CVR register holds 82 officer-related records for the company, but only five were available in the data extract reviewed, and historical (resigned/former) officers were not included. Nationality is not disclosed in the reviewed CVR data for any listed individual.
Sources
- Danish Business Authority β CVR (Central Business Register), https://datacvr.virk.dk, register data synced 15 September 2026
- LEO Foundation, "Jesper Brandgaard new Chairman of the Board of Directors of LEO Pharma," https://leo-foundation.org/en/2021/07/01/jesper-brandgaard-new-chairman-of-the-board-of-directors-of-leo-pharma/, published 1 July 2021
- LEO Pharma, "LEO Pharma appoints Christophe Bourdon as new CEO," https://www.leo-pharma.com/media-center/news/leo-pharma-appoints-christophe-bourdon-as-new-ceo, retrieved 16 September 2026
- LEO Pharma, "Jesper Brandgaard," Board of Directors biography, https://www.leo-pharma.com/who-we-are/our-governance/board-of-directors/jesper-brandgaard, retrieved 16 September 2026
Registry feed — rows exactly as filed with Danish Business Authority β CVR (Central Business Register), including entries the profile above does not cover.
Group Structure
Group structure of LEO Pharma A/S
LEO Pharma A/S is part of a verified corporate group headed by Leo Fondet (the LEO Foundation), a Danish enterprise foundation (registration number DK 11623336) established in 1984. Danish CVR-linked registry data and the LEO Foundation’s own published disclosures identify the Foundation as the ultimate parent and majority owner of the group, holding its interest in LEO Pharma A/S indirectly through the intermediate holding company LEO Holding A/S (registration number DK 39122251), which is the immediate parent recorded for LEO Pharma A/S. A minority interest of 18.23% in LEO Pharma A/S is held directly by Cidron Savanna 4 SARL, understood β based on the timing and size of Nordic Capital’s publicly announced 2021 minority investment in LEO Pharma β to be linked to Nordic Capital, though this specific entity link is not itself confirmed in the CVR register or in Nordic Capital’s public disclosures.
Beneath LEO Pharma A/S, CVR-linked corporate data records a substantial number of affiliated entities operating in numerous jurisdictions, including Norway, Ireland, the United States, Italy, Japan, the Czech Republic, Slovakia, Belgium, China, the United Kingdom, Switzerland, Canada, Sweden, Austria, the Netherlands, Spain, Greece, South Korea, Finland, Australia, New Zealand, Turkey, Mexico, Germany, France, Russia and Portugal, reflecting LEO Pharma’s stated commercial and manufacturing presence in over 100 countries. Registered names generally follow the "LEO Pharma" or "Leo Pharma" naming pattern (for example, LEO Laboratories Limited in Ireland and the UK, LEO Pharma Inc. in the US and Canada, and LEO Pharma GmbH in Germany). Because this linkage data was not individually cross-verified against each country’s own registry, these entities are classified as affiliates rather than as confirmed direct or indirect subsidiaries.
The corporate-linkage data underlying this structure was synced from company registry sources on 15 September 2026. Ownership percentages for individual downstream affiliates are not disclosed in the available data.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Leo Fondet (LEO Foundation) | DK | DK 11623336 | Ultimate parent | Ownership percentage not disclosed | Active | 2026-09-15 |
| LEO Holding A/S | DK | DK 39122251 | Immediate parent | Ownership percentage not disclosed | Active | 2026-09-15 |
| Cidron Savanna 4 SARL | Not disclosed | Not disclosed | Direct minority shareholder | 18.23% | Active | 2026-09-14 |
| LEO Laboratories Limited | IE | IE 16885 | Affiliate | Ownership percentage not disclosed | Active | 2026-09-15 |
| LEO Pharma Inc. | US | US NJ 4724539 | Affiliate | Ownership percentage not disclosed | Active | 2026-09-15 |
| LEO Pharma GmbH | DE | DE 63065B11088 | Affiliate | Ownership percentage not disclosed | Active | 2026-09-15 |
Recent structural changes
- Nordic Capital completed a minority investment in LEO Pharma, closing 22 July 2021, alongside the LEO Foundation’s continued majority ownership (source: LEO Foundation).
- Jesper Brandgaard’s appointment as Chairman of the Board followed the Nordic Capital transaction, effective 1 August 2021.
Data availability
Group structure information is partial. The immediate and ultimate parent are identifiable through CVR-linked registry data and are corroborated by official LEO Foundation and Nordic Capital disclosures, but ownership percentages for downstream affiliates and the precise identity of the Cidron Savanna 4 SARL entity are not independently confirmed beyond the registry record and reasonable inference from public deal disclosures.
Sources
- Danish Business Authority β CVR (Central Business Register), https://datacvr.virk.dk, register data synced 15 September 2026
- LEO Foundation, "Ownership," https://leo-foundation.org/en/ownership/, retrieved 16 September 2026
- Nordic Capital, press release, 23 March 2021, https://www.nordiccapital.com/insights/press-releases/leo-foundation-and-nordic-capital-partner-up-to-further-strengthen-leo-pharma-s-leading-position-in-medical-dermatology/
- LEO Foundation, "The LEO Foundation announces closing of Nordic Capital’s investment in LEO Pharma," 22 July 2021, https://leo-foundation.org/en/2021/07/22/the-leo-foundation-announces-closing-of-nordic-capitals-investment-in-leo-pharma/
Registry feed — rows exactly as filed with Danish Business Authority β CVR (Central Business Register), including entries the profile above does not cover.
Leo Fondet
Denmark
Frequently asked questions
What does LEO PHARMA A/S do?
LEO Pharma A/S is a Danish pharmaceutical company specialising in medical dermatology, researching, manufacturing and marketing treatments for skin conditions such as psoriasis and actinic keratosis, and distributing products in more than 100 countries.
Who owns LEO PHARMA A/S?
Per the Danish CVR register, LEO Holding A/S holds 81.77% and Cidron Savanna 4 SARL holds 18.23% of LEO Pharma A/S, as of data verified 14 September 2026.
Who is LEO PHARMA A/S's UBO (Ultimate Beneficial Owner)?
The Danish CVR register lists Karin Jexner Hamberg and Anja Boisen as registered beneficial owners ("Reelle ejere") of LEO Pharma A/S, without a disclosed effective ownership percentage.
What is LEO PHARMA A/S's company registration number?
LEO PHARMA A/S's registration number is 56759514, filed with Danish Business Authority β CVR (Central Business Register) in Denmark. Its current status on the register is active.
Is LEO PHARMA A/S still an active company?
LEO PHARMA A/S's status on Danish Business Authority β CVR (Central Business Register) is listed as active.
When was LEO PHARMA A/S incorporated?
LEO PHARMA A/S was incorporated on 10 February 1962, according to Danish Business Authority β CVR (Central Business Register).
What is LEO PHARMA A/S's registered address?
The registered address on file for LEO PHARMA A/S is Ballerup, Denmark.
What is LEO PHARMA A/S's revenue?
LEO Pharma's wider group reported consolidated revenue of DKK 12,453 million for the 2024 financial year, per the company's own 2024 annual results announcement; this is a group-level figure, not a standalone LEO Pharma A/S entity figure.
Is LEO PHARMA A/S listed on a stock exchange?
LEO Pharma A/S is privately held and is not listed on any stock exchange.
Who are the officers/directors of LEO PHARMA A/S?
Jesper Brandgaard has served as Chairman of the Board of Directors of LEO Pharma since 1 August 2021; Christophe Bourdon has served as Chief Executive Officer since 1 April 2022, per LEO Pharma's and LEO Foundation's official disclosures.
Does LEO PHARMA A/S have a parent company or subsidiaries?
LEO Pharma A/S is ultimately owned by Leo Fondet (the LEO Foundation), a Danish enterprise foundation, via the intermediate holding company LEO Holding A/S, with a minority stake held by Cidron Savanna 4 SARL linked to Nordic Capital's 2021 investment.